Clinical Trial: Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07151560) titled 'Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial' on Aug. 25.

Brief Summary: This study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS (BI-DFS) and safety.

Study Start Date: Aug. 30

Study Type: INTERVENTIONAL

Condition: Urology

Intervention: DRUG: 6 cycle RC48 and JS001

Different medication cyc...